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Abstract
Background: The identification of key target nodes within complex molecular networks remains
a common objective in scientific research. The results of pathway analyses are usually sets of fairly
complex networks or functional processes that are deemed relevant to the condition represented
by the molecular profile. To be useful in a research or clinical laboratory, the results need to be
translated to the level of testable hypotheses about individual genes and proteins within the
condition of interest.
Results: In this paper we describe novel computational methodology capable of predicting key
regulatory genes and proteins in disease- and condition-specific biological networks. The algorithm
builds shortest path network connecting condition-specific genes (e.g. differentially expressed
genes) using global database of protein interactions from MetaCore. We evaluate the number of
all paths traversing each node in the shortest path network in relation to the total number of paths
going via the same node in the global network. Using these numbers and the relative size of the
initial data set, we determine the statistical significance of the network connectivity provided
through each node. We applied this method to gene expression data from psoriasis patients and
identified many confirmed biological targets of psoriasis and suggested several new targets. Using
predicted regulatory nodes we were able to reconstruct disease pathways that are in excellent
agreement with the current knowledge on the pathogenesis of psoriasis.
Conclusion: The systematic and automated approach described in this paper is readily applicable
to uncovering high-quality therapeutic targets, and holds great promise for developing network-
based combinational treatment strategies for a wide range of diseases.
Background
While the utility of systems biology tools and approaches
are increasing within scientific research, several funda-
mental challenges have limited their wide-spread adop-
tion in both the basic and translational sciences. The
identification of truly relevant networks that are causa-
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tively associated with the phenotype of interest is para-
mount to the field of systems biology [1-3]. Beyond the
identification of an integrated network of interest, further
analysis of the system is required to identify key target
nodes that may represent novel therapeutic targets, or tar-
gets of the existing pharmacopeia. Beyond discovery, it is
equally important to begin to consider how our expand-
ing knowledge of molecular interactions may be trans-
lated into clinical applications in the area of molecular
diagnostics and/or targeted therapeutics. Each of these
areas requires the development of a more robust and sys-
tematic systems biology tool kit to permit the automated
construction and further analysis of molecular networks.
The publicly available molecular datasets anchored to
well-characterized disease phenotypes provide an excel-
lent framework upon which such methods can be devel-
oped and further validated.
In the typical pathway analysis, the first step is the identi-
fication of a characteristic molecule set from experimental
data (e.g., differentially expressed genes associated with
disease of interest). The association of experimentally
identified genes and/or proteins with available pathway
and protein interaction data provides the foundation for
further analysis. This can be accomplished with the help
of integrated commercial solutions such as MetaCore™
(GeneGo, Inc., St. Joseph, MI) [4], IPA (Ingenuity Sys-
tems, Mountain View, CA) or by combining publicly
available tools such as Cytoscape [5] with internal or pub-
lic protein interaction and pathway databases. The recon-
struction of condition-specific networks is often based on
the fact that biological networks are highly modular. In
general, network modules refer to a group of directly con-
nected or closely located (in terms of network distance)
proteins in the global network that work together to
achieve a distinct biological function [6,7].
Different variations of the shortest-path algorithm often
serve to extract network modules, ultimately aiming to
uncover the most-affected biological processes in condi-
tion-specific pathways. The algorithms are found either as
built-in network reconstruction tools within commercial
software packages or as open-source plug-in modules for
Cytoscape. However, one fundamental issue facing this
approach is the high interconnectivity seen in the biolog-
ical networks due to the presence of a small number of
hubs, that is, network nodes with hundreds or even thou-
sands of connections [8]. In many cases, the shortest path
between two nodes will logically traverse such hub(s).
Although some of these connections may be biologically
meaningful, many are artifacts arising from the presence
of hubs in the network. Further analysis of network topol-
ogy and graph statistics is needed to find pathways that
are truly significant for a given molecular profile.
Several attempts have been made to address the artifacts
generated by the small number of hubs in the biological
network. Croes et al. [9], for example, proposed to weight
nodes in metabolic networks based on their connectivity,
giving a penalty to highly connected metabolites. Their
results showed significant improvement in the accuracy of
predicting known metabolic pathways: the authors
reported up to 93.7% accuracy for predicting known reac-
tion steps in pathways between pairs of metabolites.
Another approach, implemented in MetaCore™, uses well-
established canonical pathways as shortcuts while gener-
ating shortest paths in protein signaling networks. The
algorithm gives preference to known signaling routes
while reconstructing condition-specific networks. Recent
work by Yu et. al [10] shifts the emphasis from high-
degree hubs to nodes that are "bottlenecks" in the net-
work, i.e., nodes that have a disproportional number of
shortest paths going through them.
These approaches have potentially severe limitations.
Always penalizing hubs might exclude them in situations
where they play a truly important role in a condition-spe-
cific network. By the same token, always giving preference
to known pathways limits the ability to generate new
hypotheses in important signaling cascades. One
approach to address this problem would be to consider
the network topology in the context of a particular dataset
(for example, a set of genes differentially expressed in a
disease), and to evaluate the statistical significance of all
the shortest paths within the framework of the global con-
nectivity map.
Another fundamental issue in pathway analysis is how to
use the results in guiding further laboratory research and
clinical applications. The results of pathway analyses are
usually sets of fairly complex networks or functional proc-
esses that are deemed relevant to the condition repre-
sented by the molecular profile. To be useful in a research
or clinical laboratory, the results need to be translated to
the level of testable hypotheses about individual genes
and proteins within the condition of interest. Systems
biology has become a key component in drug and
biomarker discovery, to identify both the causative targets
in disease networks in addition to potential biomarkers of
target disruption. In such areas, systems biology is often
used to create a hypothesis about a specific condition, and
identify a small number of molecules that can be further
interrogated in the laboratory for clear-cut answers to con-
firm or refute the hypothesis.
In this work, we present a method and associated compu-
tational algorithm which addresses the fundamental
issues described above. Our method scores nodes in a net-
work built from a set of experimentally derived, condi-
tion-specific genomic or proteomic profiles. The scoring isBMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
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based on the role the nodes play in providing connectivity
among genes or proteins of interest relative to their role in
the global network. The method is therefore neutral with
respect to the node's degree or centrality, i.e., the role of
nodes with a high degree of physical connections is neu-
tralized. Scores for truly significant nodes are enhanced,
while the scores of those that appear in the networks by
chance are reduced. In addition, the output of our algo-
rithm is a set of prioritized network nodes along with their
possible regulatory effects on other genes and proteins.
This output provides the researcher with a series of scored
and testable hypotheses associating individual compo-
nents of the identified molecular network(s) with the phe-
notype of interest.
Results
Consistent with other systems biology methodologies, the
algorithm described here starts with a set of experimen-
tally identified network nodes. In this study, we used pre-
viously published data from a microarray study of
psoriatic lesions [11]. In this work gene expression was
assayed in four patients with psoriasis using HUG95A
Affymetrix microarray platform. The skin samples were
taken from the same area of skin before and after the
lesions receded; this kept any variation in gene expression
profiles not related to the disease to a minimum. A t-test
of gene expression was performed to compare lesions and
healthy skin. Two hundred sixty-six genes were identified
by the authors as being differentially expressed in psoria-
sis (p < 0.05, Additional file 1). This set of genes was
mapped onto the global database of protein-protein inter-
actions available in GeneGo's MetaCore™ platform. This
database is a commercially available resource containing
over 200,000 protein-protein and protein-small molecule
interactions manually extracted from the literature by a
group of experts. The method described can be readily
applied to any of the publicly available protein-protein
interaction databases such as BIND [12], DIP [13], HPRD
[14] and IntAct [15].
To address the issue of network hubs providing most of
the shortest path connectivity in biological networks, we
assessed the relative contribution of every node in a con-
dition-specific network relative to its role in the global
network (see "Methods" section for algorithm descrip-
tion). Thus, the hubs which do not have any special role
related to the set of differentially expressed genes were
penalized, even though they may be highly connected. On
the other hand, nodes that are truly relevant for providing
connectivity among experimentally derived genes were
highly scored regardless of the total number of interac-
tions they have. We refer to this procedure as "topological
significance scoring" because its results depend on the
topology of protein network and define significance of a
node with respect to providing network connectivity
among the genes or proteins of interest.
Initial validation with a set of publicly available data on 
psoriasis
We used 266 differentially expressed genes identified by t-
test statistics (p < 0.05) in [11] as the input set and applied
the algorithm described in the Methods section. In the
algorithm, all network nodes corresponding to genes
from the input list are considered "sources" and "targets",
the source node being the starting point and the target
node being the endpoint of directed shortest paths con-
necting differentially expressed genes among themselves.
The rest of the nodes that the shortest path consists of are
the "internal" nodes necessary to connect the source to the
target node. The resulting condition-specific shortest path
network (CSSPN) contained 3,652 internal nodes (Addi-
tional file 2). Each of these nodes was assigned a p-value
according to the procedure described in the Methods sec-
tion. One hundred forty-five of the differentially
expressed genes from the input set were also internal to
the network and thus were assigned p-values (Additional
file 3). The rest of the differentially expressed genes were
only present as sources or targets of directed pathways.
To evaluate whether or not the nodes deemed significant
by our method are disease-related, we performed an auto-
mated search of abstracts in PubMed to find co-occur-
rence of the gene or protein name and the word
"psoriasis" for all the proteins and genes that corre-
sponded to nodes in the shortest path network (total of
3,652 nodes). It is understood that only some papers in
which the names co-occur describe a functional relation-
ship between the protein/gene and disease. However, it is
reasonable to assume that the proportion of papers
describing actual gene-disease relationships is independ-
ent of the node topological significance assigned by our
method. Thus, co-occurrence frequency can serve as a rel-
ative measure of the algorithm's performance.
In the first test, we pooled nodes into "significance bins"
according to the order of magnitude of p-values our algo-
rithm assigned. We then evaluated the fraction of all
nodes in each bin which are associated with psoriasis by
literature hits. The results shown in Figure 1a indicate that
as many as 60% of the highest-scored nodes (p < 1e-05)
co-occur in the literature with psoriasis. This compares
with a mean of only 12% among the nodes whose p-value
is > 0.1. This provides a good initial indication that our
method can identify disease-related network nodes.
Next, we needed to verify that we are selecting genes spe-
cifically related to psoriasis rather than being generally
well-studied genes that would have a high publication
rate related to any disease context. Figure 1b shows theBMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
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(A) Fraction of genes with at least one co-occurrence with the word "psoriasis" in PubMed Figure 1
(A) Fraction of genes with at least one co-occurrence with the word "psoriasis" in PubMed. Genes corresponding 
to network nodes having small p-values show a significantly higher chance to co-occur with the word "psoriasis" than a random 
set of genes (red line). (B) Co-occurrence of a gene with the word "psoriasis", as a fraction of total number of PubMed hits for 
that gene. By normalizing by total number of hits per gene, we demonstrate that genes with small p-values indeed show signifi-
cantly higher relevance to the disease.BMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
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number of papers in which the gene's name co-occurs
with the word "psoriasis" as a fraction of total number of
papers mentioning that gene. Again, we see significant
enrichment among highly scored nodes relative to the rest
of the nodes in the set. To verify if the high-scored nodes
are specifically related to psoriasis, we performed the
search on the same set of genes for other diseases. We
searched the number of papers in which the same genes
and the world 'glaucoma' or 'cancer' co-occurs. As we
expected, we did not find a positive correlation between
the high scoring nodes and the number of literature hits
(see Additional file 4 for glaucoma). We also tested our
algorithm on another autoimmune disease, multiple scle-
rosis. The scaling of the pubmed hits was not as good as it
was in the case of "psoriasis", but for low p values the frac-
tion of hits was still slightly higher. This is expected
because both diseases are autoimmune and therefore they
probably share some of the affected pathways (Additional
file 4). Collectively, these data confirm that the algorithm
assigns high scores to psoriasis-related genes using this
publically available dataset. Importantly, many of these
high-scored network nodes are not differentially
expressed in the microarray data set, but were inferred by
the algorithm from the differentially expressed gene pat-
tern and the analysis of network connectivity.
As described above, approximately half of the genes differ-
entially expressed in association with the psoriasis pheno-
type were also identified within the shortest paths
network and therefore assigned p-value scores based on
topological significance. To further explore this subset of
genes, we generated a plot similar to that in Figure 1,
showing the number of papers in which the name of a
gene and disease co-occur as a fraction of all papers writ-
ten about that gene (Figure 2). In this case the statistics are
restricted only to differentially expressed genes. Genes
with small p-values have a substantially higher fraction of
hits with "psoriasis" than differentially expressed genes on
average. The fraction of papers with "psoriasis" hits for all
differentially expressed genes is on average 0.008, while
for those with p-values < 1e-05, the fraction reaches 0.028.
Thus, using the method of literature-based confirmation,
the network topology-based algorithm is able to effec-
tively prioritize differentially expressed genes identified
from analysis of this single psoriasis data set.
Functional validation of the protein prioritization 
algorithm
Based upon the results above, it would appear that highly
scored network nodes are more likely to be associated
with the disease phenotype relative to all other nodes in
the shortest path network and differentially expressed
nodes. To investigate these results further, we conducted a
thorough functional study of the highly scored nodes
from our analysis of psoriasis gene expression using the
standard MetaCore™ software suite. We loaded two sets of
genes into the software. The first set contained 266 differ-
entially expressed genes identified by the t-test. The sec-
ond set contained genes identified as topologically
significant members of the shortest path network connect-
ing differentially expressed genes. Genes were selected
from the 3,652 genes by applying false discovery rate
(FDR) filtering by rank-order of their topological p-values.
A total of 202 genes passed FDR filtering using the exper-
iment significance level of 0.001 (Additional file 5). First,
we computed the global functional distribution of the
data, in which each dataset was mapped onto the Meta-
Core™ collection of functional pathway maps (510 maps
representing major functional blocks in cell signaling and
metabolism). These maps are freely available http://
www.millipore.com/pathways/pw/pathways. Enrichment
statistics were calculated for these two data sets in the 510
cell signaling and metabolic function blocks in Meta-
Core™ assuming a hypergeometric distribution. The false
discovery rate filter with an experiment significance level
of 0.01 was applied to account for the fact that we are test-
ing the significance of over 500 maps and the result may
contain some false positives. Top scoring maps with
detailed description were included in Additional file 4.
To visualize the significance level of individual maps, a
histogram of -log(p-value) is plotted showing each dataset
separately (Figure 3). Orange bars represent enrichment
of pathways for genes highly scored by our algorithm;
blue bars represent enrichment in differentially expressed
genes. Table 1 shows significant pathways for the com-
bined dataset constructed as a union of topologically sig-
nificant and differentially expressed genes. It is clear that
statistically significant pathway maps have high relevance
to inflammation, cell cycle, and cell adhesion processes.
These results are in very good agreement with known facts
regarding the role of these processes in the pathogenesis
of psoriasis. The analysis of topologically high scoring
nodes for down regulated genes in psoriasis resulted in
similar conclusions for both the PubMed hits and func-
tional analysis (Additional file 4).
The top-scored map for the combined dataset is the IFN-
gamma signaling pathway (Table 1). A high level of satu-
ration of this pathway with topologically significant
nodes is in excellent agreement with the current views on
the pathogenesis of psoriasis. The function of the inflam-
matory processes that induce the migration of interferon
gamma-producing Th1 lymphocytes into the skin is
thought to be central to the development of psoriasis.
These Th1 lymphocytes are responsible for the pathologic
reactions in psoriatic skin leading to keratinocyte hyper-
proliferation, small vessel proliferation, and neutrophilic
infiltration [16]. Interestingly, the second top-scoring
map is prolactin signaling. Even though the role of prol-BMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
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actin in psoriasis is not completely clear [17,18], recent
studies suggest that it may enhance IFN-gamma-induced
CXCL9, CXCL10, and CXCL11 production in keratinoc-
ytes via activation of STAT1, NF-kappaB, and IRF-1
through the JAK2 and MEK/ERK pathways and thus may
promote type 1 T-cell infiltration into psoriatic lesions
[19].
Further mechanistic investigation of the maps reveals that
combining differentially expressed genes and topologi-
cally significant nodes helps to reconstruct a more com-
plete picture of disease-related pathways, with topological
scoring indentifying key elements of the pathways that are
missed by gene expression profiling. Figure 4 shows the
top-scoring IFN-gamma signaling pathway map. Individ-
ual sets of data are represented by small thermometer-like
icons next to proteins. The set of topologically scored pro-
teins is labeled #1 and the set of differentially expressed
genes is #2. Two trends are visible on this map. First, some
key genes known to be related to psoriasis are cross-vali-
dated by both high topological scores and differential
expression (two thermometers are present next to these
proteins). The examples include STAT1, an important ele-
ment in transducing IFN-gamma signals, and p38, the key
regulator of apoptosis and stress response. Both of these
molecules are highly implicated in signaling related to the
disease [19]. Second, many important elements of the
pathway are identified by topological scoring alone. These
Co-occurrence with the word "psoriasis" for differentially expressed genes as a fraction of total number of PubMed hits Figure 2
Co-occurrence with the word "psoriasis" for differentially expressed genes as a fraction of total number of 
PubMed hits. Due to the high interconnectivity of biological networks, many differentially expressed genes are also part of 
the shortest path network and were therefore assigned a p-value. Genes that are both differentially expressed and scored 
highly for network topology show the most relevance and specificity to psoriasis. Figure 1b shows that results presented here 
are not simply due to the fact that genes with small p-values are also the best studied.BMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
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include IFN-gamma which triggers this pathway as well as
IRF-1, PKC-delta, CaMK II, CBP and other important
modulators of this pathway's activity. Even though these
molecules were not identified as differentially expressed,
their selection by the topological scoring algorithm allows
reconstruction of a much more complete picture of this
key pathway. While IFN-gamma [20], IRF-1 [19,21] and
CBP [22,23] were already associated with psoriasis in
independent studies, there is no direct evidence in the lit-
erature regarding involvement of PKC-delta and CaMKII
in the disease. On the other hand, some studies indicate
that other PKC isozimes [24] and calcium signaling in
general [25] may play role in the pathogenesis of psoria-
sis. Generally, molecules such as protein kinases are
unlikely to change their expression levels in a way that is
detectable by current microarray techniques. Nonetheless,
such molecules often play key regulatory roles in disease-
affected pathways. Topological scoring identifies them
due to their central position in signaling cascades connect-
ing differentially expressed genes. The proposed algo-
rithm is capable of performing a dual task: cross validating
disease target genes initially identified by gene expression
and suggesting a pivotal role for new targets that could not
be inferred from gene expression profiling alone.
Functional hubs and "drugable" network modules
When our algorithm is applied, a network node can be
assigned multiple p-values, each relating it to one of the
differentially expressed genes (See Methods section for
details). The p-value can be viewed as the strength of a
"functional link" between the node in the shortest path
and the differentially expressed gene. Strong functional
link (small p-value assigned by our method) implies that
the node in the shortest path plays a key role in providing
connectivity between the gene and the rest of the differen-
tially expressed set. Some nodes may have many func-
Enrichment of pathway maps in differentially expressed (blue bars) and high-scored (orange bars) genes Figure 3
Enrichment of pathway maps in differentially expressed (blue bars) and high-scored (orange bars) genes. Many 
inflammatory processes are enriched in high-scored genes, in good agreement with known close relation between psoriasis and 
inflammation. Distributions are computed using MetaCore™.BMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
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tional links with good strength. We call such nodes
"functional hubs" (see Methods).
We investigated topologically significant nodes and func-
tional hubs which resulted from the analysis of psoriasis
gene expression data in the context of known treatments
for this disease. As the first step, all nodes with high topo-
logical scores were screened against the database of targets
for drugs currently on the market or molecules in the
development pipeline and were ranked based on their
"drugability". From the set of 202 topologically signifi-
cant genes for psoriasis, we identified 97 proteins which
are drug targets based on the drug content of MetaCore™
(Additional file 6). We also identified 20 out of the 97
proteins as functional hubs (see Methods). A literature
search of the top five proteins from the topologically sig-
nificant nodes revealed that four of them were targets for
drugs documented to have a positive effect on psoriasis:
chondroitin sulfate [26], retinoic acid [27], mycopheno-
late mofetil [28], and alclometasone dipropionate [29].
Some drugs had multiple targets from our list. For exam-
ple, retinoic acid targets were enriched in the list of topo-
logically significant proteins. Indeed, 20% of the top 20
proteins and 25% of the functional hubs were targets for
retinoic acid, which is higher than the 10% of the set of
differentially expressed genes being targets for the same
drug. This is in good agreement with the fact that retinoic
acid is a widely used treatment in dermatology, including
psoriasis [27]. Furthermore, although 50% of the func-
tional hubs were targets for at least one of the above-men-
tioned drugs (compared with 10% for the differential
genes), there was only one functional hub identified as
also being differentially expressed, Interferon regulatory
factor 9. These results serve as an additional validation of
our technique, showing that it is able to identify many
known psoriasis drug targets while indicating that func-
tional hubs could be used to predict likely new targets.
To gain further insight into functional hubs and their rel-
evance to psoriasis, we built network modules consisting
of sets of genes linked to hubs by upstream or down-
stream functional connections. The genes corresponding
to these modules were mapped onto standard Gene
Ontology and other process and disease ontologies avail-
able in MetaCore™ [30]. This allowed us to prioritize func-
tional hubs based on their relevance to psoriasis-related
processes or psoriasis-related genes. We obtained 18 func-
tional hubs and corresponding network modules that
were enriched in genes related to skin diseases and condi-
tions (for enrichment analysis of modules, see Additional
file 7). Out of 11 modules for divergence hubs, 5 were
enriched in skin diseases, while out of 20 modules for
convergence hubs, 13 were enriched in skin diseases.
Notably, this analysis allowed identification of 5 potential
novel targets, i.e., proteins that are functional hubs with
relevance to skin disease, but for which no drug informa-
tion was found. These are ROR-alpha, NFKBIA, Thom-
bospondin 1, KNG, and NF-kB1 (highlighted by yellow in
Additional file 7).
Thus, the end-result of our analysis of a disease gene
expression profile is a set of network modules (originating
from functional hubs) prioritized based on their potential
functional impact and drug availability. For each module,
the analysis identifies affected biological processes and
disease-related genes. We call these sub-networks drugable
network modules. An example of such a module is gener-
ated from interferon regulatory factor 1 (IRF-1), which is
identified as one of the "divergence" hubs functionally
linked to multiple downstream targets (Figure 5). Func-
Table 1: Top scoring maps for a combined set of differentially expressed genes and topologically significant proteins. 
Map Map Folders Cell process p-value Gene
s
IFN gamma signaling pathway Immune response cytokine and chemokine mediated signaling pathway, 
immune response
1.88E-26 32/63
Prolactin receptor signaling Growth factors intracellular receptor-mediated signaling pathway, 
response to hormone stimulus
4.57E-24 30/62
Regulation of G1/S transition (part 2) Cell cycle control cell cycle 3.30E-22 22/33
Chemokines and adhesion Cell adhesion cytokine and chemokine mediated signaling pathway, 
cell adhesion
6.46E-22 45/174
EGF signaling pathway Epidermal cell differentiation intracellular receptor-mediated signaling pathway, 
response to extracellular stimulus
4.89E-21 28/64
PDGF signaling via STATs and NF-kB Growth and differentiation intracellular receptor-mediated signaling pathway, 
response to extracellular stimulus
5.18E-21 23/40
IGF-RI signaling Growth and differentiation intracellular receptor-mediated signaling pathway, 
response to extracellular stimulus
1.63E-20 29/72
AKT signaling Function groups/Kinases protein kinase cascade 5.96E-19 25/57
TGF, WNT and cytoskeletal remodeling Cell adhesion cell adhesion 6.15E-19 45/204
In the "Genes" column the first figure is the number of genes from the combined dataset on each map, the second figure is the total number of 
genes represented on each map.BMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
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tional links were imported into MetaCore™ using Meta-
Link™, a parser for interaction data. The network was
analyzed with respect to the disease-related genes (as
recorded in MetaCore™), and the result shows that it has
high relevance to skin diseases, with about 75% of its
nodes associated with this disease category (for enrich-
ment of all modules, see Additional file 7).
Discussion
In this study we have introduced a novel procedure for
assigning topological significance scores to nodes in pro-
tein interaction networks. The scoring is based on node's
role in providing the shortest paths connectivity among
genes or proteins from experimentally-derived set. There
are several advantages of this method which make it a
powerful tool in the analysis of high-throughput molecu-
lar data such as gene expression or proteomics profiles.
First, our method generates significance scores based on
the input of a particular molecular profile, such as a set of
differentially expressed genes. Thus it finds nodes that are
significant with respect to a condition or a disease repre-
sented by such profile. This can be contrasted with general
IFN-gamma signaling pathway Figure 4
IFN-gamma signaling pathway. Mapped on the pathway are the set of high-scored network nodes (set #1) and the set of 
differentially expressed genes (set #2). The datasets are visualized by thermometer-like symbols next to protein icons. Differ-
entially expressed genes with a well-established relation to disease (e.g. STAT1, c-Myc) are cross-validated by high statistical 
scoring. Many additional important elements of the pathway are identified by topological scoring – IFN-gamma, IRF-1, PKC-
delta, CaMK II, CBP.BMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
Page 10 of 14
(page number not for citation purposes)
topological properties of network nodes such as clustering
coefficient, centrality and degree which characterize nodes
independently of any condition-specific molecular data.
Second, it assigns scores to all nodes participating in the
shortest path network, whether or not they are part of the
input experimental set. Therefore it allows identification
of many important elements of signal transduction path-
ways which themselves do not come up as differentially
expressed genes or proteins.
In this study we have tested the ability of our approach to
identify network nodes associated with a selected disease
(psoriasis) using the input of empirically defined differen-
tially expressed genes, and to predict which network
nodes are key mediators of the disease phenotype through
the analysis of network topology. As an indication of suc-
cess, nodes which are assigned high significance (small p-
values) by our algorithm are also several times more likely
to be related to psoriasis in the literature, than nodes with
low significance. The result shows that our approach can
be applied as a "sorting" method for prioritizing gene and
protein sets from high throughput assays. For example,
many microarray studies yield hundreds of differentially
expressed genes. Pursuing further research on all of them
is prohibitively expensive. High topological scores
assigned to some of these genes could serve as additional
evidence, helping to select most promising candidates for
detailed investigation. Topological scoring could also
point to several new candidates – genes with exceptionally
high topological scores that do not display differential
expression. For example, our analysis assigned high signif-
icance scores to several protein kinases and transcription
factors (IRF-1, CaMKII, PKC, etc.) which are not differen-
tially expressed themselves but whose activity was inferred
based on significant downstream effects reflected in the
gene expression profile. As shown above, some of these
proteins (IRF-1, PKC-beta) were already linked to psoria-
sis in other independent studies, while others (CaMKII,
PKC-delta) may represent novel targets.
Mechanistic investigation of highly scored network nodes
shows that many of them play key roles in pathways for
IRF-1 functional disease network reconstructed from psoriasis expression profile Figure 5
IRF-1 functional disease network reconstructed from psoriasis expression profile. The network was generated 
from psoriasis data as described in the "Results" section. IRF-1(left) was identified as a "divergence" hub functionally linked to 
multiple downstream target genes differentially expressed in psoriasis. Functional links are highlighted in pink. In MetaCore we 
have also reconstructed possible physical pathways underlying functional influence (thin lines). The network has 75% of its 
nodes associated with skin diseases by annotations in MetaCore.BMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
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inflammation, cell cycle, and cell adhesion – all highly
associated with the pathogenesis of psoriasis. These path-
ways are highly enriched in topologically significant
nodes overall. This indicates that topologically significant
nodes can be used for identifying molecular mechanisms
of the disease or condition of interest. When pathway
enrichment analysis is performed for both differentially
expressed genes and topologically significant nodes the
results are dominated by maps strongly enriched in topo-
logically significant nodes (Figure 3). This is due to the
fact that topologically significant nodes tend to represent
key regulatory elements of signaling cascades, while dif-
ferentially expressed genes are more likely to be found
among target genes whose expression is regulated by these
cascades. By design, expertly compiled pathway maps
tend to focus on signaling cascades – bearers of core func-
tionality. Target genes which in many cases could be reg-
ulated by multiple signaling pathways tend not to be
concentrated on any particular map. Moreover, many key
regulators have hundreds of target genes and not nearly all
of them are represented on pathway maps. Hence the
enrichment analysis of topologically significant nodes
reveals signaling pathways containing proteins that have
high relevance to regulation of differentially expressed tar-
get genes as a group, even though target genes themselves
are not well represented on maps for these pathways.
In addition to topological scoring, our method assigns
"functional links" between differentially expressed genes
and nodes in the shortest paths. Nodes with multiple
functional links represent "functional hubs". Functional
hubs are condition-specific: their functional links are
determined by topological scoring procedure and defined
in the context of a particular condition-specific molecular
profile. Many functional hubs themselves do not have
large numbers of direct physical interactions with other
proteins. Rather they provide unique "bridges" between
multiple differentially expressed genes. Some functional
hubs may have the majority of their links downstream
while others have them upstream. The first type of hub is
essentially "in control" of many functionally significant
connections, while the second type is "being controlled"
by a multitude of such connections. Thus we suggest that
these "divergence" and "convergence" hubs may play fun-
damentally different roles in the disease and drug
response, and affecting them with a drug may have differ-
ent consequences. We consider functional hubs to be pri-
ority drug targets, because of their key positions in
pathways regulating multiple genes whose expression is
affected in disease. Since special role of functional hubs is
defined with respect to a disease-specific dataset, it is quite
possible that at least some of them play just a minimal
role in signaling pathways under normal conditions.
Thus, unlike nodes with many physical interactions, tar-
geting functional hubs with drugs is more likely to maxi-
mize impact on the disease while minimizing effects on
general physiological processes.
Our analysis also suggests that network modules centered
on functional hubs are likely to be relevant to the disease
phenotype, in this case psoriasis. Importantly, such mod-
ules can be readily tested in the lab by affecting corre-
sponding hubs by drugs or other methods, such as RNA
interference. This opens new possibilities in systemati-
cally predicting and validating drug targets by using the
concept of drugable network modules.
Conclusion
We developed a novel statistical approach for scoring net-
work nodes in the protein interaction network for their
relevance to a disease phenotype or other condition of
interest. This scoring is accomplished through a combined
analysis of high throughput molecular assays and topol-
ogy of the protein network. We applied our method to
gene expression profiles from psoriasis patients and iden-
tified many known and several new drug targets for pso-
riasis and biological pathways in which they participate.
These findings were in excellent agreement with the cur-
rent knowledge on the pathogenesis of psoriasis. Finally,
we introduced the concept of functional hubs and corre-
sponding "drugable" network modules. Our analysis sug-
gests that these modules are the most promising
candidates to be targeted by drugs in order to maximize
the impact on the disease. The results indicate that our
approach opens new possibilities for systematic identifi-
cation of the new promising drug targets and prioritizing
them for further detailed investigation.
Methods
Algorithm for node prioritization and reconstructing 
significant pathway modules
Topological scoring of nodes
Our algorithm starts with a set of experimentally identi-
fied network nodes. To understand how this algorithm
works, let's assume that K  is a set of experimentally
derived nodes of interest (e.g., nodes representing differ-
entially expressed genes). K is a subset of a global network
of size N. The first step is the construction of a directed
shortest path network connecting each node in K to other
nodes in K, traversing via other nodes in the global net-
work. If there are multiple shortest paths of equal length
between two nodes in K, then all of the nodes from the
multiple paths are included in the shortest path network
for that pair, S, which is a subset of N and contains nodes
in addition to K. Some nodes from K may become "inter-
nal" in S, that is, they are lying on the shortest paths, while
the rest are either "source" or "target" terminals of the
shortest paths (Figure 6). All nodes in S that are not in K
are by definition "internal" nodes. For future reference, we
call S a condition-specific shortest path network (CSSPN).BMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
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The building of this shortest path network is executed by
a modified version of the standard breadth-first search
described elsewhere (for details, see for example [31]).
Let us consider node i ∈ S, an internal node, and j ∈ K, one
of the nodes of the experimental set. In addition to S, we
calculate the shortest paths between j  and every other
node (except i) in the global network, wherever such
shortest paths exist (up to N-2 pairs). Then we count how
many of these node pairs have node i present in at least
one of the shortest paths; this number is Nij ≤ N-2. On the
other hand, we count how many times node i occurs in at
least one shortest path of node pairs when connecting j to
all other nodes in K. This number is Kij ≤ Kj ≤ K-1 (we
assume node i is not differentially expressed; otherwise Kj
≤ K-2). Note that we count node i only once for every pair
from K, even though it may be part of multiple linear
shortest paths connecting the same pair.
Under the "null" hypothesis, node i has no special role in
connecting node j to the rest of differentially expressed
genes in K. Thus, the probability of finding i in the short-
est paths connecting Kij or a larger number of node pairs
originating or terminating at node j follows a cumulative
hypergeometric distribution. This problem can be recast
as selection without replacement. Nij node pairs contain-
ing i as an internal node in the shortest paths connecting
j to all other nodes in the global network can be consid-
ered as a set of "marked" node pairs. On the other hand,
a set of K-1 pairs consisting of the node j and the rest of K-
1 experimentally derived nodes represent a "selection". If
node i has no special role for connecting j to the rest of the
nodes in K, then the number of marked shortest path net-
works in the selection should follow the hypergeometric
distribution
where pij(Kij) is the probability of finding node i in the
shortest paths connecting Kij number of node pairs in the
differentially expressed set among those originating or ter-
minating at node j. The p-value is calculated as the cumu-
lative distribution of the function above. We repeat this
procedure for all nodes in K, calculating up to K p-values
for each node i in the network of shortest paths connect-
ing differentially expressed genes. Each of these p-values
shows relevance of node i to individual members of the
set K. As we want to identify the nodes that are statistically
significant to at least one or more members of the experi-
mental set, we define the "topological significance" score
associated with node i as the minimum of the pij values.
We note that our method, unlike betweenness centrality
does not count the actual number of shortest paths
between the pairs of nodes, but rather it counts the
number of instances a node is part of the shortest path
network between the node pairs. More importantly, our
technique considers fractions of differentially and non-
differentially expressed genes connected by shortest paths
containing the node that is being evaluated. In this con-
text it is not concerned with the paths bypassing the node
of interest. In contrast, the betweenness centrality meas-
ure is based on relative numbers of shortest paths going
via the node of interest and those bypassing it.
Upon request the authors will provide the topological
scoring algorithm code and a publicly accessible hyper-
link for a web-based version of the algorithm.
pK
Nij
Kij
NN ij
KK ij
N
K
ij ij () . =
⎛
⎝
⎜
⎜
⎞
⎠
⎟
⎟
−−
−−
⎛
⎝
⎜
⎜
⎞
⎠
⎟
⎟
−
−
⎛
⎝
⎜
⎞
⎠
⎟
2
1
2
1
Set of experimentally derived nodes K is colored red Figure 6
Set of experimentally derived nodes K is colored red. 
We connect them by shortest path network S (blue nodes). 
The rest of the global network is represented by black 
nodes. In this example, the size of the global network N = 13, 
K = 7, and S = 5. The number of possible shortest path net-
works between node B and each of the other nodes in the 
global network which can contain D is 11 (N-2). The number 
of such networks which contain node D is 7 (NBD = 7). On 
the other hand, the number of shortest path networks con-
taining D, among those connecting only nodes from the set K, 
is 5 (KBD = 5). The significance (p-value) for node D with 
respect to node B and set K can be calculated as pBD = p(N-2, 
NBD, K-1, KBD). Similarly, we can calculate the other p-values 
for D with respect to A, G, K, J, I, and L, and then pick the 
smallest value and assign it as the significance of node D in 
the sub-network defined by the nodes of interest (red 
nodes). The nodes can be classified as internal (F, D, C, H, and 
M), source (A, B, and L) and target (A, G, K, J, and I) nodes.BMC Systems Biology 2009, 3:36 http://www.biomedcentral.com/1752-0509/3/36
Page 13 of 14
(page number not for citation purposes)
Directionality and functional hubs
For any node j, the shortest paths connecting it to other
nodes could be divided into two categories: those leading
from node j to other nodes and those leading to node j
from other nodes. From the perspective of an internal
node i connecting j to other nodes in K, these will be
"incoming" and "outgoing" paths, respectively. In the calcu-
lations described above, we bundled these two sets of
paths into a single number, Kij, representing overall con-
nectivity. On the other hand, we can also consider them
separately. The procedure for this is similar to the one
described above. Thus, we end up with two p-values, pin
and pout, respectively. The p-value score can be viewed as
the strength of the incoming or outgoing "functional link"
between the internal node and the differentially expressed
gene. The lower the p-value, the stronger functional link
is. In the psoriasis study, nodes having at least 10 incom-
ing or outgoing functional links below the p-value thresh-
old of 10-4 were considered convergence or divergence
"functional hubs", respectively.
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